Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jelle W Kylstra"'
Autor:
Rashmi Chugh, Judy S. Wang, Anthony J. Olszanski, Breelyn A. Wilky, Paul Algate, Leah Plato, Alexander I. Spira, Borys Korchin, Jelle W. Kylstra
Publikováno v:
Journal of Clinical Oncology. 40:2611-2611
2611 Background: PSB205 is a new biological agent consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1) expressed in a fixed ratio (2:1) from a single cell-line, manufactured as one product and dispensed from a sing
Autor:
Gilles Salles, Ama Z. S. Rohatiner, Jelle W. Kylstra, Hervé Tilly, Barbara Botto, Pierre Soubeyran, Achiel Van Hoof, Angelika Bischof-Delaloye, Franck Morschhauser, Anton Hagenbeek, Wim L.J. van Putten, John Radford
Publikováno v:
Journal of clinical oncology, 31(16), 1977-1983. American Society of Clinical Oncology
Purpose Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 (90Y) –ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. Patients and Methods P
Autor:
Kenneth Sumida, Kazuhiro Sakamoto, Nancy L. Furumoto, Jelle W. Kylstra, Junji Machi, Robert H. Oishi, Andrew J. Oishi
Publikováno v:
The Cancer Journal. 12:318-326
PURPOSE Long-term follow-up data of radiofrequency ablation (RFA) for patients with unresectable metastatic liver tumors from colorectal cancer have rarely been reported. This study was undertaken to evaluate long-term outcome of RFA in relation to i
Autor:
Herbert Y. Meltzer, Lisa A Arvanitis, Vincent T Ciuryla, Anastasia M. Wilson, Anthony F. Lehman, Jelle W Kylstra, Walter W Hong, Ihor W Rak, William T. Carpenter
Publikováno v:
Schizophrenia Research. 32:51-58
Treating schizophrenia is expensive. Preventing rehospitalization of patients with schizophrenia provides an attractive opportunity for cost savings, especially for patients with 'revolving-door' or multiple-episode schizophrenia. Reducing the occurr
Autor:
Patrick A, Burch, Gary A, Croghan, Dennis A, Gastineau, Lori A, Jones, Judith S, Kaur, Jelle W, Kylstra, Ronald L, Richardson, Frank H, Valone, Stanimir, Vuk-Pavlović
Publikováno v:
The Prostate. 60(3)
Prostate cancer is the most commonly diagnosed malignancy in American men, yet treatment of its metastatic androgen-independent form remains inadequate. This mandates development of new therapies such as immunotherapy. In this Phase 2 trial, we deter